Cogent Biosciences, Inc. (COGT): Shareholders' Equity
$636.37M
As of 2025-12-31
$532.39M
As of 2026-06-30
+35.5%
3-year compound annual growth
+22.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $636.37M | +148.3% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $256.29M | -0.6% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $257.80M | +0.8% | 2026-02-17, Balance as of period end |
| 2022-12-31 | $255.74M | +19.4% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $214.18M | -8.7% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $234.67M | +638.8% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $31.76M | -47.3% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $60.23M | n/m | 2020-03-26, Balance as of period end |
| 2017-12-31 | -$48.85M | n/a | 2019-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | 2025-12-31 | $636.37M | +148.3% |
| Praxis Precision Medicines, Inc. (PRAX) | 2025-12-31 | $878.14M | +97.1% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$2.09B | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $722.17M | +7.5% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $956.82M | -6.4% |
| Xencor Inc (XNCR) | 2025-12-31 | $635.59M | -6.2% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $314.69M | +39.5% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $648.02M | +191.4% |
Compare COGT, PRAX, BBIO, VRDN side by side · Screen every company in Pharmaceutical Preparations ↗